Investor Orbimed Capital Llc
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Orbimed Capital Llc . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-14 13G/A SIBN / SI-BONE, Inc. 2,969,500 2,184,200
2025-05-15 13G/A SIBN / SI-BONE, Inc. 3,249,500 2,969,500
2024-11-14 13G/A SIBN / SI-BONE, Inc. 2,305,300 3,249,500
2023-02-14 13G/A MIST / Milestone Pharmaceuticals Inc. 2,583,821 0
2023-02-14 13G/A CYBN / Cybin Inc. 11,291,300 6,153,299
2022-02-11 13G SIBN / SI-BONE, Inc. 2,305,300
2022-02-11 13G/A MIST / Milestone Pharmaceuticals Inc. 2,493,109 2,583,821
2022-02-11 13G CYBN / Cybin Inc. 11,291,300
2022-02-11 13G/A APTO / Aptose Biosciences Inc. 8,030,000 0
2021-02-12 13G MIST / Milestone Pharmaceuticals Inc. 2,493,109
2021-02-12 13G APTO / Aptose Biosciences Inc. 8,030,000
2020-02-14 13G/A FOMX / Foamix Pharmaceuticals Ltd. 5,195,330 2,577,982
2019-02-13 13G FOMX / Foamix Pharmaceuticals Ltd. 5,195,330 5,195,330
2019-02-12 13G FOMX / Foamix Pharmaceuticals Ltd. 5,195,330